News
ImmunOs Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)
– Preclinical data highlighting mode-of-action of lead program iosH2
ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced that the Company will present a scientific poster at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting (SITC) which will be held November 10-14, 2021, in Washington, DC, USA.
Launch of Capitainer® B Vanadate, a blood sampling card that eliminates the risk of inaccurate test results when analyzing PEth
Swedish medtech scaleup Capitainer today announced the launch of its proprietary patent pending blood sampling card, Capitainer B Vanadate for accurate analysis of PEth, a key marker for long term alcohol use/abuse.
Dried Blood Spot (DBS) sampling has been proposed as a method to solve the problem of post sampling formation of PEth occurring in traditional venous blood samples. However, the hematocrit effect gives negative impact on the accuracy due to uncertainty of the blood volume in DBS. Capitainer B Vanadate solves both problems in the same device and creates a new better standard.
T-knife Therapeutics Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
— Presentations to cover preclinical data for lead TCR-T candidate, TK-8001, and the protocol design for a Phase 1/2 trial of TK-8001 to treat MAGE-A1 positive solid tumors
T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced that three abstracts highlighting its lead product candidate TK-8001, a T cell receptor (TCR) engineered T cell therapy (TCR-T) being developed to treat MAGE-A1 positive solid tumors, will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting taking place November 10-14, 2021.
ImmunOs Therapeutics Appoints Claudia Berger as SVP Clinical Development
– Strengthened clinical development expertise to ensure smooth transition into the clinic
Schlieren (Zurich Area), Switzerland. ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced that Claudia Berger has been appointed as Senior Vice President Clinical Development, further strengthening the Company’s clinical development and operations expertise as it prepares for initial clinical trials.